Guggenheim Initiates Buy on Cullinan Therapeutics with $30 Target
Guggenheim starts coverage on Cullinan Therapeutics with a Buy rating, citing promising Phase 1 data for T-cell engagers in autoimmune diseases and AML.
/ 904 items
#Healthcare↓
FDA Requests More Data for Joenja in Younger Children with APDS
Pharming (PHAR) receives FDA Complete Response Letter for Joenja (leniolisib) in children aged 4-11 with APDS. Additional data needed on dosing and testing methods.
Guggenheim Gives Avalo Therapeutics a Buy Rating on AVTX-009
Guggenheim starts coverage of Avalo Therapeutics with a Buy rating, highlighting AVTX-009 as a promising IL-1beta treatment for Hidradenitis suppurativa (HS) and $2.1B peak sales potential.
FDA Contradicts Corcept: Agency Says It Warned Biotech About Drug Rejection Risk
FDA reveals it warned Corcept Therapeutics multiple times about relacorilant's approval issues before the company submitted its Cushing's syndrome drug application.
ALX Oncology Raises $150 Million to Fund Cancer Treatment Research
ALX Oncology announces $150 million stock offering to advance clinical trials for evorpacept and ALX2004 cancer therapies with support from major investors.
Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know
Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.